悦康药业：子公司YKYY025注射液获美国FDA临床试验批准

Group 1 - The company, Jiangsu Tianlong, announced on January 10 that it has received a notice from the U.S. Food and Drug Administration (FDA) regarding the clinical trial of YKYY025 injection for the prevention of lower respiratory diseases caused by Respiratory Syncytial Virus (RSV) [1]